EMAIL TO A FRIEND COMMENT

 

FDA Expands Use of Xarelto to Treat and Reduce Recurrence of Blood Clots


The FDA expanded the approved use of Xarelto (rivaroxaban) to include treating deep vein thrombosis (DVT) or pulmonary embolism (PE), and to reduce the risk of recurrent DVT and PE following initial treatment. Xarelto is already FDA-approved to reduce the risk of DVTs and PEs occurring after knee or hip replacement surgery, and to reduce the risk of stroke in people who have a type of abnormal heart rhythm called non-valvular atrial fibrillation.

 

Blood clots occur when blood thickens and clumps together. DVT is a blood clot that forms in a vein deep in the body. Most deep vein blood clots occur in the lower leg or thigh. When a blood clot in a deep vein breaks off and travels to an artery in the lungs and blocks blood flow, it results in a potentially deadly condition called PE.

 

The FDA reviewed Xarelto’s new indication under the agency’s priority review program, which provides an expedited six-month review for drugs that offer major advances in treatment or that provide treatment when no adequate therapy exists.

 

“Xarelto is the first oral anti-clotting drug approved to treat and reduce the recurrence of blood clots since the approval of warfarin nearly 60 years ago,” said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. Other drugs approved by FDA to treat or reduce the risk of blood clots include Lovenox (enoxaparin), generic versions of enoxaparin, Arixtra (fondaparinux), Fragmin (dalteparin), Coumadin (warfarin), and heparin.

 

The major side effect observed with Xarelto is bleeding, similar to other anti-clotting drugs.

 

See the FDA Announcement

 

 

REPRINTS & PERMISSIONS COMMENT